Lung adenocarcinoma taking ositinib in advanced stage usually does not need to be reviewed once a month, and it is recommended to be reviewed once every 3 months if the disease is stable. Patients with advanced non-small cell lung cancer with EGFR exon 19 deletion, L858R exon 21 substitution or EGFR T790M mutation confirmed by genetic testing can use oxitinib targeting these mutations to control tumor progression. As a third-generation EGFR mutation-targeted drug, ositinib not only solves the problem of drug resistance of the previous two generations of targeted drugs, but also has better efficacy and fewer side effects, which can enable patients with lung adenocarcinoma to achieve a longer progression-free survival. As long as there is no drug resistance in patients taking OXITINI, the tumor generally will not show obvious progress, and it is enough to review the CT examination every three months, if the interval of review is too short, it is not only meaningless, but also unfavorable to the health of the body receiving frequent X-ray irradiation. If there is any change in your condition, you can temporarily increase the frequency of review under the guidance of your doctor, so do not be negligent to avoid delays in your condition. Please strictly follow the doctor’s instructions for medication, and do not use medication on your own.